We previously showed that equilibrative nucleoside transporter 1 (ENT1) is a primary ribavirin transporter in human hepatocytes. However, because the role of this transporter in the antiviral mechanism of the drug remains unclear, the present study aimed to elucidate the role of ENT1 in ribavirin antiviral action. OR6 cells, a hepatitis C virus (HCV) replication system, were used to evaluate both ribavirin uptake and efficacy. The ribavirin transporter in OR6 cells was identified by mRNA expression analyses and transport assays. Nitrobenzylmercaptopurine riboside (NBMPR) and micro-RNA targeted to ENT1 mRNA (miR-ENT1) were used to reduce the ribavirin uptake level in OR6 cells. Our results showed that ribavirin antiviral activity was associated with its accumulation in OR6 cells, which was also closely associated with the uptake of the drug. It was found that the primary ribavirin transporter in OR6 cells was ENT1 and that inhibition of ENT1-mediated ribavirin uptake by NBMPR significantly attenuated the antiviral activity of the drug as well as its accumulation in OR6 cells. The results also showed that even a small reduction in the ENT1-mediated ribavirin uptake, achieved in this case using miR-ENT1, caused a significant decrease in its antiviral activity, thus indicating that the ENT1-mediated ribavirin uptake level determined its antiviral activity level in OR6 cells. In conclusion, our results show that by facilitating its uptake and accumulation in OR6 cells, ENT1 plays a pivotal role in the antiviral effectiveness of ribavirin and therefore provides an important insight into the efficacy of the drug in anti-HCV therapy.C hronic hepatitis C is a major cause of liver cirrhosis and hepatocellular carcinoma, and a combination of interferon-␣ (IFN-␣) and ribavirin is a standard anti-hepatitis C virus (HCV) therapy. Since the addition of ribavirin to IFN-␣ significantly improves the rate of sustained virologic response (SVR) (40 to 60% in genotype 1 patients) (5), the drug plays a key role in current anti-HCV therapy.Ribavirin, a purine nucleoside analog, is phosphorylated intracellularly to form mono-, di-, and tri-phosphates, which then accumulate within cells at high concentrations (4, 13). While the primary anti-HCV mechanisms of the drug are still under debate, it is considered likely that the important actions take place within the cells themselves, and several mechanisms have been proposed to explain what occurs there. These include inhibition of inosine monophosphate dehydrogenase (reviewed in references 4 and 7 and references therein). Additionally, a recent study revealed that ribavirin potentiates IFN-␣ action by augmenting IFN-stimulated induction of gene expression (16).Taking into consideration the above-mentioned mechanisms, it is reasonable to assume that the uptake of ribavirin into hepatocytes is a prerequisite for its antiviral activity. Since ribavirin is a hydrophilic molecule, import of the drug into cells requires host nucleoside transporters, which are divided into two families: equilibra...
Ribavirin is a purine nucleoside analogue that possesses potent anti-hepatitis C virus activity, and it has long been considered likely that ribavirin undergoes a first-pass metabolism at the small intestine. Although purine nucleoside phosphorylase (PNP) is assumed to be involved in this metabolism, this has not been conclusively demonstrated. Furthermore, no pharmacogenomic studies related to PNP-mediated ribavirin phosphorolysis have previously been conducted. In this study, we sought to identify the role of PNP in ribavirin phosphorolysis in the human small intestine, and to clarify the effect of the single nucleotide polymorphism (rs1049564) on PNP's ribavirin phosphorolysis activity. The results of our investigations show that PNP is abundantly expressed in the human small intestine, and that intestinal ribavirin phosphorolysis is severely inhibited by ganciclovir, a PNP-inhibitor. Therefore, PNP is likely to play a primary role in the ribavirin phosphorolysis in the human small intestine. On the other hand, the results of our attempt to clarify the function of rs1049564 show that it does not affect PNP's ribavirin phosphorolysis activity. We believe that the present study will facilitate further pharmacogenomic and biochemical characterization of PNP as a key metabolic enzyme of ribavirin.
PurposeAcotiamide, a gastroprokinetic agent used to treat functional dyspepsia, is transported to at least two compartments in rat stomach. However, the role of these stomach compartments in pharmacokinetics and pharmacodynamics of acotiamide remains unclear. Thus, the purpose of this study was to elucidate the relationship of the blood and stomach concentration of acotiamide with its inhibitory effect on acetylcholinesterase (AChE).MethodsConcentration profiles of acotiamide and acetylcholine (ACh) were determined after intravenous administration to rats and analyzed by physiologically-based pharmacokinetic and pharmacodynamic (PBPK/PD) model containing vascular space, precursor pool and deep pool of stomach.ResultsAcotiamide was eliminated from the blood and stomach in a biexponential manner. Our PBPK/PD model estimated that acotiamide concentration in the precursor pool exceeded 2 μM at approximately 2 h after administration. Acotiamide inhibited AChE activity in vitro with a 50% inhibitory concentration of 1.79 μM. ACh reached the maximum concentration at 2 h after administration.ConclusionsOur PBPK model well described the profile of acotiamide and ACh concentration in the stomach in the assumption that acotiamide was distributed by carrier mediated process and inhibited AChE in the precursor pool of stomach. Thus, Acotiamide in the precursor pool plays an important role for producing the pharmacological action.
Concentrative nucleoside transporter 2 (CNT2) (encoded by the SLC28A2 gene) transports various antiviral or antitumor purine nucleoside analogs to be involved in their pharmacokinetics and pharmacological actions. The results of our study showed that mouse hepatocytes hardly expressed CNT2 mRNA and no CNT2-dependent nucleoside uptake was observed, while rat hepatocytes exhibited high CNT2-dependent nucleoside uptake activity levels with abundant CNT2 mRNA expression. We concluded that CNT2 contributes considerably to nucleoside uptake in rat hepatocytes but not in mouse hepatocytes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.